Introduction
The myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are clonal myeloid neoplasms characterized, at the time of their initial presentation, by the simultaneous presence of both myelodysplastic and myeloproliferative features, which prevent them from being classified as either myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN). Cytopenias and dysplastic changes of any cell line (MDS-like features) may be seen in conjunction with elevated white blood cell (WBC) counts, thrombocytosis and organomegaly, features more commonly associated with MPN. The presence of fibrosis alone in cases that are otherwise typical of myelodysplasia should not justify placement in this category, but rather considered as a MDS with fibrosis.
The three best-defined entities within the MDS/MPN group are: chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML) and juvenile myelomonocytic leukemia (JMML). The latter is a leukemic condition seen in young children that is usually considered within the group of pediatric myeloid neoplasms; 1 it will not be discussed any further in this review. Less well defined is a group of MDS/MPN disorders that are different from both CMML and aCML. Among these, the most well known is a rare overlap syndrome known as refractory anemia with ring sideroblasts and thrombocytosis (RARS-T).
Clinical symptoms and other phenotypic manifestations are caused by complications resulting from cytopenia(s), dysplastic cells that function abnormally, leukemic infiltration of various organ systems and general constitutional symptoms, such as fever and malaise.
The etiology of MDS/MPN is not known. The pathophysiology of MDS/MPN involves abnormalities in the regulation of myeloid pathways of cellular proliferation, maturation and survival. Patients with MDS/MPN do not have a Philadelphia chromosome (Ph) or BCR/ABL fusion gene. Using metaphase cytogenetics (MC), chromosomal abnormalities are found only in a proportion of patients with MDS/MPN. No specific genetic defects have been identified for any of these entities. Abnormalities in regulation of the ras pathway of signaling proteins appears to be a common finding in CMML, aCML and JMML, and may be involve in the abnormal myeloid proliferation associated with these diseases. Recent evidence has shown that high-resolution single-nucleotide polymorphism Affymetrix (SNP-A) genotyping microarrays represent an effective technique for detecting cytogenetically cryptic genomic aberrations. 2, 3 Using SNP-A, aberrations were found in around 3 of 4 of MDS/MPN (vs 37% by MC). This sensitive approach may allow stratification of these patients for early therapeutic interventions in the future. So far, however, treatment of these diseases is tailored to their clinical manifestations (myeloproliferative or myelodysplastic) that predominate in the individual patient and are responsible for the disease-associated morbidity. This results in a 'mixed bag' of cytoreductive treatment and/or interventions to ameliorate cytopenias. However, treatment with drugs capable of inducing DNA hypomethylation, such as 5-azacitidine and 5-aza-2 0 -deoxycytidine have shown promising results both in CMML and in MDS patients.
MDS/MPN: classification
The French-American-British classification scheme for myeloid disorders did not contain an overlap category. 4-6 CMML, for example, was considered to belong to the MDS category, because it shares morphologic features of dysplasia with other members of this group, frequently elevated medullary blast counts similar in range to those seen in cases of refractory anemia with excess blasts and a largely overlapping prognosis. Controversy remained as to which entities were merely variations of the same disease process (for example, a myeloproliferative variant for cases of CMML with WBC 413 000 Â 10 9 per liter) or how much proliferation was still acceptable for a diagnosis of MDS. To address these problems by recognizing that overlap between MDS and MPN sometimes occurs, the World Health Organization (WHO) created the MDS/MPN category which provides a less restrictive view of these myeloid disorders. 7 This novel approach, which recognizes the limitations of the old morphologic classifications, has provided an open framework which facilitates assimilation of new knowledge. As new molecular data become available with increasing frequency, this will require more frequent revisions to the WHO classification. During the review process, better defined entities will be assigned to separate groups based on specific defects in their molecular pathways.
Although much progress has been made in understanding the molecular pathogenesis of myeloid neoplasms, most of the diseases included in the group of MDS/MPN still remain 'clinicopathologically assigned'. 8 In other words, they can only be accurately diagnosed by a careful multiparametric approach that is based on the integration of bone marrow and peripheral blood morphology with other laboratory and clinical findings. It cannot also be overstressed the need for a correct classification right from the time of the disease outset. In cases in which the patient has been diagnosed previously elsewhere, a complete review of the original material is mandatory. All of this can only be achieved by a close collaboration between the hematopathologist and the clinical hematologist, with most diagnosis being truly 'co-signed'.
MDS/MPN: main entities
Atypical chronic myeloid leukemia aCML is a rare MDS/MPN that affects elderly patients with a median age ranging between 60 and 76 years, and with an apparent male predominance. Its incidence is o2 cases for every 100 cases of t(9;22), BCR/ABL-positive chronic myelogenous leukemia (CML). [9] [10] [11] Patients have some features of BCR/ ABL-positive CML including: splenomegaly, an elevated WBC count with a predominance of granulocytic cells, and moderate anemia. The major characteristic that distinguishes aCML from BCR/ABL-positive CML is dysgranulopoiesis, which is often severe. Occasionally, aCML may have an initial presentation more similar to CMML than CML, with a lower WBC count (it may be as low as 20 Â 10 9 per liter) and a normal to decreased platelet count. 10 Diagnosis. The diagnosis requires the presence of different findings that are summarized in Table 1 . The WBC count is increased and shifted to the left with immature granulocytes, including blast cells, promyelocytes and myelocytes, representing 10-20% of peripheral blood white cells. Dysplastic neutrophils are typically seen (Figure 1a ). Granulocytes may show typical pseudo-Pelger-Huët changes, nuclear hypolobation and/or abnormal chromatin condensation (clumping) and cytoplasmic hypogranularity. Although the absolute number of monocytes may (rarely) be high, their relative number is always less than 10%. In contrast to BCR/ABL-positive CML, basophilia is not prominent, usually accounting o2% of peripheral blood white cells.
The bone marrow is hypercellular, with an elevated myeloidto-erythroid ratio (usually less than 10:1) due to granulocytic hyperplasia ( Figure 1b ). In contrast, the amount of erythropoiesis and megakaryopoiesis is variable from case to case. Megakaryocytes can be reduced in number, particularly, in cases of aCML associated with thrombocytopenia. Although trilineage dysplasia can be seen, the dysplastic changes are usually more prominent in the granulocytic lineage. Megakaryocytic dysplasia can be similar in appearance to that seen in MDS displaying a predominance of small/dwarf forms. However, it may be less apparent in cases in which the megakaryocytes are reduced in number. An increased proportion of blasts (o20%) can be seen. The identification of these cells in bone marrow biopsies may be facilitated by immunostaining with CD34 ( Figure 1c ). 12 Mild to moderate fibrosis is also frequently seen.
Differential diagnosis. Atypical CML may superficially simulate
Ph-positive chronic myelogenous leukemia ( Figure 1a ). 9, 10, 12 Although CML is usually excluded by cytogenetic and/or molecular genetic studies, it is still important to be able to make a 'positive' morphological identification of this entity. The major distinguishing feature is dysgranulopoiesis, which can easily be appreciated by examining peripheral blood and bone marrow aspirate smears. Although some abnormalities of granulocyte nuclear lobularity and cytoplasmic appearance may also be seen in CML, particularly in the accelerated phase, aCML has significantly more severe dysplastic changes. CMML is excluded by the lack of monocytosis. Other types of MDS can be excluded by paying careful attention to the WHO guidelines. Other ancillary studies, particularly immunophenotyping studies, do not usually help unless blast cell numbers are elevated.
Genetics. Karyotypic abnormalities are reported in up to 80% of patients with aCML. The most common abnormalities are þ 8 and del (20q), but abnormalities of chromosomes 13, 14, 17, 19 and 12 are commonly reported as well. [10] [11] [12] Rarely, patients whose neoplastic cells have an isolated isochromosome 17q 13 may have features that resemble those of aCML, although most of these cases will fulfill the criteria either for CMML or for MDS/MPN, unclassifiable (see later). Although the activating JAK2V617F mutation has been reported in rare cases classified as aCML, 14 it is unclear whether those cases fulfilled all the criteria for such a diagnosis. In a recent study, co-authored by one of us, 10 patients with aCML classified according to the WHO guidelines were analyzed. None of the bone marrow specimens showed positivity for JAK2 V617F mutation. 15 The presence of rearrangement of PDGFRA or PDGFRB genes excludes a diagnosis of aCML. Although, in the past, some cases of t(8;9)(p22;p24) and the PCM1-JAK2 fusion gene have been reported as 'aCML', data currently available suggest they have eosinophilia and lack myelodysplasia and may be better regarded as CEL. 16 Meticulous description of the morphology of atypical myeloid proliferations associated with various genetic defects will be necessary to assign them to appropriate categories. Thus in many instances, the diagnosis of aCML is a diagnosis of exclusion, and requires the support of adequate cytogenetics and genetic techniques.
Prognostic considerations. Atypical CML is a more aggressive disease than CML, its overall median survival being 11-25 months. [9] [10] [11] Patients may develop acute leukemia, up to 40% at a median time from the diagnosis of 18 months, 11 or may develop complications related to bone marrow failure.
Variant: syndrome of abnormal chromatin clumping. The 'syndrome of abnormal chromatin clumping' [17] [18] [19] [20] can be considered as a variant of aCML. 10 In most patients, the WBC count is increased, but occasional patients may have normal values. The blood is characterized by the presence of neutrophilia associated with a variable proportion of immature myeloid elements, mostly myelocytes and metamyelocytes. The neutrophils and the immature cells exhibit exaggerated clumping of their nuclear chromatin ( Figure 2 ). Nuclear hypolobation and cytoplasmic hypogranularity are also commonly found. Anemia and thrombocytopenia are often severe. The bone marrow is hypercellular and shows granulocytic predominance. The myeloid cells display the same nuclear abnormalities as in the blood. Moderate dysplastic changes in the erythroblastic and megakaryocytic lineages are often present as well. Survival times are similar to those reported in aCML. 10, [17] [18] [19] [20] Chronic myelomonocytic leukemia CMML is a MDS/MPN whose typical manifestation is its peripheral blood monocytosis. 12, [21] [22] [23] [24] [25] The incidence of CMML is approximately three cases per 100 000 individuals older than 60 years. 5 It accounts for 12% of all FAB-defined MDS, resulting in a crude incidence of about 0.5 of 100 000 per year in all ages. The disease has been divided into myelodysplastic and myeloproliferative subtypes on the basis of a WBC count of 13 Â 10 9 per liter or higher for the myeloproliferative type and less than that number for the myelodysplastic type. 4 Patients with leukocytosis of 413 Â 10 9 per liter have a higher incidence of splenomegaly. [21] [22] [23] However, both subtypes show a similar degree of dysplastic changes. 23 As the percentage of bone marrow (or peripheral blood) blasts is the most important determinant of survival in CMML patients, the use of a WBC cutoff to separate the subtypes is probably arbitrary and of controversial prognostic value. 23 Diagnosis. The diagnosis (Table 1 ) requires a persistent peripheral blood monocytosis of 41 Â 10 9 per liter, with a percentage of monocytes 410% of the WBCs. The monocytes may be abnormal in appearance with bizarre nuclei and cytoplasmic granules ( Figure 3a ). Promonocytes, with more immature nuclear chromatin, and monoblasts are usually not present or represent o5% of peripheral blood cells. If blasts and promonocytes (these cells are considered as blast equivalent) account for X20% of the WBCs, the diagnosis should be acute myeloid leukemia (AML) rather than CMML. The peripheral blood may demonstrate dysplastic , such a diagnosis should never be made without examination of the bone marrow. 12 Some AMLs with monocytic blasts may show peripheral blood changes similar to those of CMML because of cytological maturation of the blast cell population in the peripheral blood. 12 The bone marrow of CMML is usually hypercellular and may demonstrate monocytic or granulocytic hyperplasia (Figures 3b  and c) . When granulocytic hyperplasia is prominent, it may be difficult to distinguish the abnormal monocyte population from myelocytes, especially if the latter cells are hypo-or degranulated. Nonspecific esterase cytochemical studies (for example, a-naphthyl butyrate esterase) may be helpful in this setting, by confirming their monocytic origin (Figure 3d ). 22 This is of particular importance in diagnosing rare cases of so-called 'marrow predominant' CMML. In these cases, although the circulating monocyte count is o1000 Â 10 9 per liter, the bone marrow shows a high percentage (410%) of monocytes. Flow cytometry with CD14, CD11c, CD64 and immunohistochemistry with CD68 (KP-1), CD163 and CD68R (PG-M1) are less useful in confirming the presence of monocytic differentiation than cytochemistry (Figure 3e ). 22, 26, 27 Additionally, by flow cytometric analysis, the blood and marrow monocytes usually express aberrant phenotypes with two or more aberrant features. 26, 27 The most common aberrant immunophenotypic characteristics are overexpression of CD56, aberrant expression of CD2, decreased expression of CD14 and decreased expression of HLA-DR, CD13, CD15, CD64 and/or CD36. 26, 27 Granulocytes may also show aberrant scatter properties and aberrant phenotypic features. An increased percentage of CD34 þ cells 22 or an emerging blast population with aberrant immunophenotype has been associated with early transformation to acute leukemia.
Erythroid precursors and megakaryocytes may demonstrate prominent dysplastic changes (Figure 3f ), but these cell types are often normal in appearance. Ringed sideroblasts are present in about 20% of the cases, 23 and about 5-10% of the patients have more than 10% ringed sideroblasts. Blast cell and promonocyte counts may be elevated up to 20%, and an elevation in blast cell numbers is associated with a poorer prognosis. 21, 28 The hypercellularity and the striking myeloproliferative appearance of the bone marrow biopsy seen in this myeloproliferative type of CMML is similar to what is seen in cases of chronic myelogenous leukemia (CML) or atypical CML (aCML). (c) CMML: In the bone marrow aspirate, it is difficult to appreciate the monocytes (which are increased) and to distinguish them from the myelocytes. (d) CMML: Naphthyl butyrate esterase facilitates the identification of monocytes and promonocytes in marrow aspirate of cases of CMML. (e) CMML: CD68 (PG-M1) highlights the presence of an increased number of monocytes. Immunohistology with antibodies reactive with monocytes/histiocytes is less useful in confirming the presence of monocytic differentiation than cytochemistry. (f) CMML: CD42 may help in identifying dysmegakaryopoietic forms frequently found in cases of CMML and also in other types of myelodysplastic/myeloproliferative neoplasms (MDS/ MPN). (g) CMML: CD123 helps in identifying plasmacytoid dendritic cells nodules, a finding which can occur in bone marrow of patients with CMML. Similar accumulations of plasmacytoid dendritic cells can be seen also in other myeloid neoplasms.
The WHO classification scheme subdivides CMML into two subcategories, depending on the number of blasts found in the peripheral blood and bone marrow. These include CMML-1 with blasts o5% in the blood or o10% in the bone marrow, and CMML-2 that is characterized by blasts 5-19% in the blood or 10-19% in the bone marrow, or when Auer rods are present and the blast count is o20% in blood or marrow. The finding of X20% blasts in the blood or the bone marrow indicates AML rather than CMML. 21 Micromegakaryocytes and/or megakaryocytes with abnormally lobated nuclei are found in up to 80% of patients. 21, 22 In contrast with CML, pseudo-Gaucher cells are usually absent. A mild to moderate increase in the amount of reticulin fibers is seen in the bone marrow of nearly 30% of patients with CMML. 21 Nodules composed of plasmacytoid dendritic cells (plasmacytoid monocytes) can be identified in the bone marrow in 20% of the cases of CMML. 22, 29 Although characteristic, they are not disease specific and can be seen in other myeloid neoplasms. 29 The nodules, which are best appreciated histologically, are composed of cells with round nuclei, finely dispersed chromatin, inconspicuous nucleoli and a rim of eosinophilic cytoplasm. Apoptotic bodies, often lying within histiocytes, are frequently present. The relationship of the plasmacytoid monocyte proliferation to the leukemic cells has been considered uncertain in the past. 21 More recent evidence has shown however that these are clonal in nature, and closely related to the associated myeloid tumor. 30 The plasmacytoid monocytes associated with CMML have a characteristic immunophenotype. They are positive for CD123 (Figure 3g ), CD14, CD43, CD68, CD68R, CD45RA, CD33 (weakly) and CD4. Granzyme B (but not Tia-1 and perforin) is also regularly expressed; 20,21,28 CD56 expression is seen in a minority of the cases, although T-cell-associated antigens such as CD2 and CD5 can also be present. They do not express other panlymphoid antigens (such as CD3, CD19 and CD20), pan-myeloid antigens (such as CD13, CD11c and myeloperoxidase) or CD34. Because of their variable positivity with some T-cell antigens, in the past they were erroneously considered plasmacytoid T cells. 31 The spleen enlargement in CMML is usually due to infiltration of the red pulp by leukemic cells. [32] [33] It is important to remember, however, that in CMML, the spleen may be the initial site of acute extramedullary transformation. In these instances, because of the myeloid-rich cellular background, it is often difficult to identify the accumulation of blasts which characterize early acute transformation. 31, 32, 34 Like in other conditions also characterized by extramedullary infiltrates, the identification of the blasts can be greatly facilitated by immunohistochemistry. 32, 34 Lymphadenopathy is uncommon, but when it occurs, it usually signals transformation to a more acute phase, that is, the lymph node may show extramedullary AML. Lymph node and less commonly spleen can also be involved by a diffuse infiltration of plasmacytoid monocytes, 29, 35, 36 producing a generalized lymphadenopathy. This rare occurrence may be the presenting manifestation of CMML.
Genetics. Clonal cytogenetic abnormalities are found in 20-40% of patients with CMML, but none is specific. [21] [22] [23] [24] [25] The most frequent recurring abnormalities include þ 8, À7/del (7q) and structural abnormalities of 12p. Abnormalities of 11q23 are uncommon in CMML, and instead suggest the diagnosis of acute leukemia. 21 5q-anomalies are also extremely rare in CMML. Their presence may suggest the alternative diagnosis of MDS/ MPN-U. In this context, it is important to exclude the possibility of a rare myeloproliferative variant characterized by the simultaneous presence of an isolated 5q-and JAK2 mutation (see later). Although patients with isolated i(17q) may have hematological features of CMML (or atypical CML), 13 most cases should also rather be considered as an unclassifiable form of MDS/MPN. Cases of MDS/MPN with eosinophilia associated with t(5;12) (q31B33;p12) and an ETV6-PDGFRB fusion gene, which were formerly included in the CMML category, are currently assigned to a novel group of myeloid neoplasm associated with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. 37 Other translocations resulting in abnormalities of PDGFRB fall also into the same group. 38 The identification of this group of diseases is clinically relevant in view of their sensitivity to imatinib treatment. However, a rare additional subset of CMML cases with eosinophilia without anomalies of PDGFRB do exist; this variant of CMML may be diagnosed when the criteria for CMML are present, but in addition, the eosinophil count in the peripheral blood is 41.5 Â 10 9 per liter. This rare subset should be designated as CMML-1 or -2 with eosinophilia according to the above guidelines. It is unclear whether patients in this rare category may also have symptoms related to the degranulation of the eosinophils similar to those seen in cases associated with genetic anomalies. Cases of CML with p190 have an intermediate hematological phenotype between CML and chronic myelomonocytic leukemia. Approximately 50% of these cases may have prominent monocytosis. 39, 40 Cytogenetics should, however, correctly assign them to the CML category. Thus, in the absence of cytogenetics, in addition to the usual PCR analysis for the presence of p210 (which is used to confirm CML), it might also be important to exclude the presence of p190. 39, 40 Although the activating JAK2V617F mutation has been reported in rare cases of CMML, 14 it is unclear whether those cases fulfilled all of the criteria for such a diagnosis. Overall its frequency seems to be around 5%. As many as 40% of patients exhibit point mutations of RAS genes at diagnosis or during the disease course. 41, 42 Although detection of RAS mutations is not generally useful for diagnosis, abnormalities involving the RAS pathway are thought to be an important mechanism for this and other chronic myeloproliferative diseases, including CML and cases associated with t(5;12) chromosome abnormality. In contrast with JMML, PTPN11 mutations are distinctively uncommon in adult patients with CMML. 43 
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Leukemia SPOTLIGHT Differential diagnosis. Cytogenetic and molecular genetic studies help in excluding Ph-positive CML. The differential diagnosis between CMML and atypical CML may be difficult, but is critical because of the worse prognosis of patients with the latter disease. Peripheral blood features are distinct, 21, 22 but some overlap may occur. Although monocytes counts may be slightly elevated in aCML, these cells do not usually exceed 10%, whereas monocytes counts in CMML are usually 410%. Besides the more severe degree of granulocyte dysplasia seen in atypical CML than in CMML, the former also demonstrates an increase in immature granulocytic cells, including blast cells, promyelocytes and myelocytes, of up to 20% in the peripheral blood; these cell types are almost always o10% in the blood of patients with CMML. Difficulties may occur in the identification of early blastic transformation in a known case of CMML. Similarly it might be tricky distinguishing CMML-2 patients from patients with acute monocytic leukemia. In these situations, the diagnosis largely depends on the exact assessment of the medullary blast count, which in some cases may be difficult (for example, in myelofibrotic marrows).
Prognostic considerations. Survival of patients with CMML
is reported to vary from 1 to more than 100 months, but the median survival time in most series is 20-40 months. [21] [22] [23] [24] [25] 44, 45 Progression to acute leukemia occurs in approximately 15-30% of cases. A number of clinical and hematological parameters, including splenomegaly, severity of anemia and degree of leukocytosis, have been reported to be important factors in predicting the course of the disease. 21 However, in virtually all studies, the percentage of blood and bone marrow blasts is the most important factor in determining survival. Table 2 and Figure 4 show that the median survival of CMML-1 patients is about 18 months as compared to only 12 months in CMML-2. The International Prognostic Scoring System (Greenberg et al. 46 ) that only included CMML cases with a WBC count ofp12 000 Â 10 9 per liter has been shown to be weak in the prognostication of CMML. The reason has to do with the fact that low cell counts and also high-risk cytogenetics are present only in a minority of CMML patients. Other scoring systems seem to be more powerful. [47] [48] [49] [50] [51] 
MDS/MPN, unclassifiable
Some cases demonstrate overlap features of both MDS and also an atypical finding(s) more suggestive of a MPN, such as marked marrow fibrosis, leukocytosis or organomegaly. Such cases may be termed MDS/MPN, unclassifiable with a comment describing the atypical findings. 52, 53 The incidence of MDS/MPN-U is low, 2% of the cases classified as MDS in one series. 52 The prognosis is poor with a median survival of 21 months. 52 In this context, it is important to stress the need of an adequate molecular characterization of these cases, which should, at a minimum include besides BCR/ABL assessment and a complete marrow karyotype, the analysis for the presence of JAK2 mutation. The latter is particularly relevant to the diagnosis of two of the MDS-MPN-related entities that are described in the following section.
Miscellaneous entities with MDS/MPN-like features
Refractory anemia with ring sideroblasts and thrombocytosis RARS-T is a rare overlap syndrome with features of refractory anemia with ring sideroblasts (RARS) associated with features seen in cases of MPN with thrombocytosis, such as essential thrombocythemia or primary myelofibrosis. 54, 55 Main features of this condition are found summarized in Table 1 . This is rare entity with a frequency of 0.7% of all FAB-defined myelodysplastic disorders, CMML included (data from the Myelodysplastic Syndromes Registry, Dü sseldorf, Germany). It shows no sex predilection or specific cytogenetic abnormality and must be differentiated from the other conditions that also display thrombocytosis, such as 5q-syndrome. The distinction between RARS-T and MPN is more problematic. The presence of RS is not an uncommon finding in MPN, and can also be found in CMML. As an isolated finding, RS are considered as insufficient to support a diagnosis of MDS rather than a MPN. Moreover, from a prognostic standpoint, the JAK2-positive cases of RARS-T (see later) appear more in line with a MPN-like excellent survival (ET) than with the rest of the MDS/MPN group. Thus, to diagnose RARS-T, the presence of dyserythropoiesis to a degree equivalent to that seen in cases of RARS is required. This must be present in an hypercellular marrow characterized by increased megakaryopoiesis (Figures 5a and b) with large MPN-like forms (Figures 5c and d) . The two conditions share a similar tendency to abnormal accumulation of iron in mitochondria-producing ringed sideroblasts (Figure 5e ). Interestingly, both RARS and RARS-T share a high frequency of hemochromatosis-associated gene mutations, a molecular Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; RARS-T, refractory anemia with ring sideroblasts and thrombocytosis. anomaly originally described in cases of RARS, which has been shown to occur also in the majority of cases of RARS-T. 56 The demonstration in RARS-T of a high frequency of positivity for JAK2 mutation, possibly acquired as a secondary genetic event, 57 can perhaps explain its relationship to a classical myeloproliferative disorder. The prognosis of RARS-T subgroup is better than that of the whole group of patients with MDS/ MPN-U. 53, 58 In one study, the RARS-T showed a median survival of 42 months, 51 a prognosis which is definitely better than that of CMML-1 or -2 patients ( Table 2 and Figure 4 ). The better prognosis may be due to presence of JAK2 positivity. 58 Conversely, the presence of a MPL mutations, a rare genetic occurrence in RARS-T (as opposed with the MPN), seems not to have pathophysiologic meaning. [59] [60] [61] Although the JAK2-positive cases of RARS-T have a better prognosis than the rest of the MDS/MPN group, it should not be forgotten that they still have a worse outcome than those with essential thrombocythemia with whom this condition may be confused. In particular, RARS-T patients are more likely to develop AML, 62 and therefore a correct diagnosis is of fundamental importance for defining the prognosis of the individual patient. The importance of performing an iron stain on a bone marrow aspirate smear, while working up a patient suspected to have a chronic myeloid neoplasm cannot therefore be overemphasized. 62
5q-/JAK2-positive atypical myeloproliferative disease
Cases of '5q-syndrome' presenting with chronic myeloproliferative disorders-like manifestations, thrombocytosis in particular, have been described in the past. 63 More recently, it has been documented that these cases are characterized by a frequency of JAK2 mutations that is higher than that seen in the 'nonmyeloproliferative' 5q-syndrome. 64 Its main features are found summarized in Table 1 . In contrast with the classical 5q-syndrome, the anemia seen in these patients is more often normochromic. Higher platelet counts and higher WBC counts are also more often seen as opposed to cases of 5q-with unmutated JAK2. In 5q-/JAK2-positive cases, the bone marrow shows a prominent myeloid proliferation (Figure 6a ). The megakaryocytes show the characteristic hypolobated or nonlobated nuclei associated with the 5q-syndrome (Figure 6b ). In contrast with the 5q-syndrome that has a relatively benign prognosis, the clinical behavior of these myeloproliferative cases seems more variable. However, lenalidomide treatment may be effective in both subtypes. 65 Atypical myeloproliferative disease associated with isolated isochromosome 17q
Additionally, a MDS/MPN-like disorder associated with isochromosome 17q has been described; 13 it occurs with a male predominance in adults and is associated with neutrophils showing severe nuclear hyposegmentation (Figure 7a) , variable monocytosis and a high rate of transformation to AML. The marrow is hypercellular and may show severe dysmegakaryopoiesis (Figure 7b ), frequently associated with myelofibrosis ( Figure 7c ). As isochromosome 17q is not recognized as a disease defining cytogenetic abnormality per se, it is uncertain whether the cases with this anomaly should be placed in a separate category, considered as a MDS/MPN unclassifiable or, in cases with monocytosis, considered as CMML for purpose of classification.
Other poorly characterized MDS/MPD neoplasms may also occur in association with mast cell disease where they represent one of the types of clonal non-mast cell lineage hematological diseases associated with systemic mastocytosis. 66 In conclusion, although eagerly awaiting a 'genetically based' classification scheme free of morphologic subjectivity, the WHO classification offers a valuable tool in the diagnosis and classification of MDS. The updating of the WHO classification of hematopoietic malignancies is well underway; changes for the MDS/MPN group are expected to be minor. The overall philosophy remains similar: a classification which is scientifically sound and of clinical value, and flexible enough to be usable worldwide. An important goal is its openness to the inclusion of new information.
